行情

INSM

INSM

Insmed
NASDAQ

实时行情|Nasdaq Last Sale

23.21
+0.07
+0.30%
盘后: 23.21 0 0.00% 17:00 12/13 EST
开盘
23.19
昨收
23.14
最高
23.36
最低
22.94
成交量
57.60万
成交额
--
52周最高
33.13
52周最低
11.31
市值
20.74亿
市盈率(TTM)
-6.3815
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

INSM 新闻

  • Did Hedge Funds Drop The Ball On Insmed Incorporated (INSM) ?
  • Insider Monkey.12/07 22:50
  • Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • PR Newswire.12/03 21:05
  • Edited Transcript of INSM earnings conference call or presentation 30-Oct-19 12:30pm GMT
  • Thomson Reuters StreetEvents.11/18 05:06
  • Insmed Appoints Dr. Clarissa Desjardins to its Board of Directors and Names Roger Adsett Chief Operating Officer
  • PR Newswire.11/14 13:00

更多

所属板块

生物技术和医学研究
+1.07%
制药与医学研究
-0.32%

热门股票

名称
价格
涨跌幅

INSM 简况

Insmed Incorporated is a global biopharmaceutical company. The Company’s product ARIKAYCE (amikacin liposome inhalation suspension) is developed for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that offers a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
展开

Webull提供Insmed Incorporated的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。